Competitive receptor binding assay to probe for agonist binding to CXCR2

doi:10.1038/nprot.2007.211

Method Article

Competitive receptor binding assay to probe for agonist binding to CXCR2

https://doi.org/10.1038/nprot.2007.211

This protocol has been posted on Protocol Exchange, an open repository of community-contributed protocols sponsored by Nature Portfolio. These protocols are posted directly on the Protocol Exchange by authors and are made freely available to the scientific community for use and comment.

Version 1

posted

You are reading this latest protocol version

Chemical biology

Drug discovery

Biochemistry

Computational biology and bioinformatics

Biological techniques

Cell biology

Developmental biology

chemokine receptor

competitive binding

agonist

receptor-ligand interactions

CXCR2

Based on an observed apparent structural homology between the monomeric structure of the cytokine MIF and the CXCL8 dimer, we have tested whether MIF can directly interact with the cognate CXCL8 receptor CXCR2. Using a competitive receptor binding assay and other biochemical interaction assays, we found that MIF in fact directly binds to CXCR2 with a nanomolar affinity comparable to that observed for the cognate ligand CXCL8 (ref. 1).

125I -labeled recombinant CXCL8 (IM249, Amersham)

125I-labeled recombinant CXCL12 (IM314, Amersham)

Recombinant CXCL8 (PeproTech EC/CellConcept, Umkirch, Germany)

HEK293 cells stably expressing CXCR2 (from Ben-Baruch Lab, Tel-Aviv, Israel)²

Liquid scintillation cocktail, Aquasafe 500 plus (Zinsser Analytic, Frankfurt)

Wallac 1409 DSA liquid scintillation counter (PerkinElmer)

Competitive inhibition of CXCL8 binding to CXCR2 receptor by CXCR2 agonist

Cultivate cells endogenously expressing or stably overexpressing CXCR2 (i.e. HEK293-CXCR2 cells) (10⁵ cells/mL) in a 24-well plate in DMEM medium plus 10% FCS overnight.
Remove the medium and add binding buffer (medium without FCS).
Put the plate on ice for 10 min.
Add cold agonist, i.e. rMIF or cold CXCL8 (0 – 1 µM) together with the tracer (40 pM of 125I -labeled recombinant CXCL8).
Perform equilibrium receptor binding for 90 min at 4 °C.
Remove the medium and wash the cells twice with cold medium.
Harvest the cells by adding 0.5 M NaOH.
Transfer the lysate to a liquid scintillation tube.
Add Aquasafe 500 plus LSC cocktail and mix well.
Determine the cell-bound radioactivity by liquid scintillation counting.
For most agonist-receptor interactions, assume that receptor binding inhibition by agonist (i.e. rMIF or cold CXCL8) follows a one-site model.
Calculate the EC₅₀, K_i and K_d values by using the equation of Cheng and Prusoff for heterologous competition experiments, applying the GraphPad software.

Overall 2 days

Binding assay including counting per se 3-4 h

It is advised to use adherent cells. If using such cells, avoid disturbing cell adhesion during washing steps.

See for example Bernhagen et al., Nat. Med. 2007.

Bernhagen, J. et al. MIF is a non-cognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. Epub ahead of print(2007).
Ben-Baruch, A. et al. IL-8 and NAP-2 differ in their capacities to bind and chemoattract 293 cells transfected with either IL-8 receptor type A or type B. Cytokine 9, 37-45 (1997).

We sincerely thank Dr. A. Ben-Baruch (Department of Cell Research and Immunology, Tel Aviv University, Israel) for making available the HEK293-CXCR2 cells for us.

Download PDF

Version 1

posted

You are reading this latest protocol version

Competitive receptor binding assay to probe for agonist binding to CXCR2

Status:

Version 1

Introduction

Reagents

Equipment

Procedure

Timing

Critical Steps

Anticipated Results

References

Acknowledgements

Associated Publications

Status:

Version 1

Privacy Policy

Terms of Service

Competitive receptor binding assay to probe for agonist binding to CXCR2

Status:

Version 1

Introduction

Reagents

Equipment

Procedure

Timing

Critical Steps

Anticipated Results

References

Acknowledgements

Associated Publications

Status:

Version 1

Privacy Policy

Terms of Service

Manage Cookie Preferences